Especifique uma ação ou criptomoeda na barra de pesquisa para obter um resumo
Heidelberg Pharma AG
HPHAHeidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company is developing HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for the treatment of gastrointestinal tumors. It is also developing TLX250-CDx, a diagnostic antibody for diagnosing renal cancer that is in Phase III trials; and triple-negative breast cancer. In addition, the company develops TLX250 (girentuximab), a diagnostic antibody, which is in Phase II study for patients with advanced clear cell renal cell carcinoma; RHB-107, an oral serine protease inhibitor that is in Phase II study to treat COVID-19. It has licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. for the development and commercialization rights for HDP-101 and HDP-103 in Asia. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is based in Ladenburg, Germany. Address: Gregor-Mendel-Strasse 22, Ladenburg, Germany, 68526
Analytics
Preço Alvo de Wall Street
11.77 EURRácio P/E
–Rendimento de dividendos
–Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Figuras chave HPHA
Análise de Dividendos HPHA
Crescimento de dividendos em 5 anos
–Crescimento contínuo
–Taxa de pagamento em média de 5 anos
–Histórico de Dividendos HPHA
Avaliação de ações HPHA
Relatório HPHA
Acompanhe as principais métricas de cada ação em um só lugar, sem complicações
Inscreva-se no premiumResultados | 2019 | Dinâmica |